Since the implementation of the new version of the Drug Administration Law, industry supervision has become stricter, and relevant departments have repeatedly struck hard to strictly investigate whether the production and operation behavior of pharmaceutical companies complies with the regulations, and in this context, many pharmaceutical companies have been fined
for the production and sale of counterfeit drugs, environmental protection, and failure to correct problems.
On November 28, the Hunan Provincial Food and Drug Administration issued an administrative penalty decision, and Hunan Zhengqiao Traditional Chinese Medicine Pieces Co.
, Ltd.
produced and sold inferior drug forsythia, and was fined and confiscated 360,919 yuan
.
In fact, since the beginning of this year, there have been countless cases of pharmaceutical companies being fined for the production and sale of inferior drugs
.
For example, on October 25, the Fujian Provincial Drug Administration released a number of administrative punishment information and announced a number of inferior drug cases
.
Among them, the Administrative Punishment Information Disclosure Form (2022.
10.
25 Fuzhou Office) announced four cases, three of which were inferior drug cases
.
The "Administrative Punishment Information Disclosure Form (2022.
10.
25 Baisheng + Rongseng)" announced two cases of inferior drugs
.
On October 10, the Yunnan Provincial Food and Drug Administration released two administrative punishment information disclosure data
.
According to the announcement, Longling County Shenlong Oxygen Plant had previously been investigated for providing drugs to others for unlicensed production, and the Food and Drug Administration gave it a "warning" and fined it 5,000 yuan; Yunnan Chengtou Xinyi Pharmaceutical Co.
, Ltd.
was found to be selling counterfeit drug madder, and the circumstances were minor, and eventually only the counterfeit drug and illegal gains
were confiscated.
.
.
.
.
.
.
In this regard, the industry generally believes that with the implementation and advancement of the new version of the drug administration law and the tightening of the supervision of the pharmaceutical industry, the illegal sale of inferior drugs by these pharmaceutical companies has been exposed one after another, which will continue to wake up the industry
.
It is worth noting that in addition to being fined for the production and sale of counterfeit drugs, since November, there have been many pharmaceutical companies that have been fined for failing to comply with good management practices for drug sales and failing to correct problems
.
On November 21, the Liaoning Provincial Food and Drug Administration issued two announcements of administrative punishment results
.
Among them, Yingkou Laobian Pharmacy Pharmaceutical Chain Co.
, Ltd.
was found to have failed to comply with the quality management practices for drug operation, and the regulatory department ordered rectification within a time limit, and after the expiration date, the relevant departments reviewed and found that they had not corrected within the time limit, and according to relevant laws and regulations, they were fined 100,000 yuan
.
In addition, on November 18, the Liaoning Provincial Food and Drug Administration notified that Liaoning Xinsheng Xitang Pharmaceutical Chain Co.
, Ltd.
failed to comply with the quality management practices for drug sales, failed to make corrections within the time limit, and was fined 100,000 yuan, and the fine was paid
in installments until October 31, 2023.
On November 14, the Liaoning Provincial Food and Drug Administration announced that Yingkou Xinjiuding Pharmacy Chain Co.
, Ltd.
failed to comply with the quality management practices for drug business and failed to correct it within the time limit, and was fined 100,000 yuan, and the fine was paid in installments before October 31
, 2023.
It is worth mentioning that a large number of medical device companies have also been punished
for the production, sale and use of unqualified medical devices.
For example, recently the website of the Shenzhen Market Supervision Bureau disclosed a news
that a company was fined more than 160,000 yuan for producing Class II medical devices that did not meet the technical requirements of the product.
On November 23, an administrative penalty information published on the website of the Hunan Provincial Drug Administration (the administrative penalty decision showed that a medical protective mask produced by a medical device company in Hunan that did not meet the requirements of mandatory standards was fined
720,000 yuan.
On November 10, the Wuxi Municipal Administration for Market Regulation issued a penalty decision
.
A hospital in Wuxi was suspected of using unregistered medical devices without qualified documents, Article 89 of the Regulations on the Supervision and Administration of Medical Devices, and imposed a fine of 62,000 yuan
.
Industry analysts believe that from the current situation of the industry, the current attention of the pharmaceutical industry to product safety is increasing, and the corresponding supervision is becoming more and more stringent
.
In this context, for pharmaceutical companies and machinery companies, only by standardizing operations and continuously improving product quality can we better "survive
".
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
